ELANCO ANIMAL HEALTH INC (5EA.DE) Stock Price, Forecast & Analysis

FRA:5EA • US28414H1032

21.715 EUR
+0.88 (+4.22%)
Last: Feb 12, 2026, 07:00 PM

5EA.DE Key Statistics, Chart & Performance

Key Statistics
Market Cap10.79B
Revenue(TTM)4.59B
Net Income(TTM)36.00M
Shares496.86M
Float491.27M
52 Week HighN/A
52 Week LowN/A
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)0.81
PE26.81
Fwd PE24.45
Earnings (Next)02-24
IPO2018-09-20
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
5EA.DE short term performance overview.The bars show the price performance of 5EA.DE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 5 10

5EA.DE long term performance overview.The bars show the price performance of 5EA.DE in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of 5EA.DE is 21.715 EUR. In the past month the price increased by 14.92%.

ELANCO ANIMAL HEALTH INC / 5EA Daily stock chart

5EA.DE Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to 5EA.DE.


Chartmill TA Rating
Chartmill Setup Rating
5EA.DE Full Technical Analysis Report

5EA.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to 5EA.DE. 5EA.DE may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
5EA.DE Full Fundamental Analysis Report

5EA.DE Financial Highlights

Over the last trailing twelve months 5EA.DE reported a non-GAAP Earnings per Share(EPS) of 0.81. The EPS increased by 12.94% compared to the year before.


Industry RankSector Rank
PM (TTM) 0.78%
ROA 0.27%
ROE 0.53%
Debt/Equity 0.59
Chartmill High Growth Momentum
EPS Q2Q%46.15%
Sales Q2Q%10.39%
EPS 1Y (TTM)12.94%
Revenue 1Y (TTM)3.08%
5EA.DE financials

5EA.DE Forecast & Estimates

22 analysts have analysed 5EA.DE and the average price target is 22.15 EUR. This implies a price increase of 1.99% is expected in the next year compared to the current price of 21.715.

For the next year, analysts expect an EPS growth of 5.08% and a revenue growth 5.5% for 5EA.DE


Analysts
Analysts84.55
Price Target22.15 (2%)
EPS Next Y5.08%
Revenue Next Year5.5%
5EA.DE Analyst Estimates5EA.DE Analyst Ratings

5EA.DE Ownership

Ownership
Inst Owners116.54%
Ins Owners0.99%
Short Float %N/A
Short RatioN/A
5EA.DE Ownership

About 5EA.DE

Company Profile

5EA logo image Elanco Animal Health, Inc. develops, manufactures, and markets products for pets and farm animals. The company is headquartered in Indianapolis, Indiana and currently employs 9,000 full-time employees. The company went IPO on 2018-09-20. The firm's product portfolio is sold in more than 90 countries and serves animals across many species, primarily dogs and cats (collectively, pet health) and cattle, poultry, swine, and sheep (collectively, farm animal). The company has a diverse portfolio of products marketed under approximately 200 brands, including products for both pets and farm animals. The firm's global pet health portfolio is focused on parasiticides, vaccines and therapeutics. Its pet health products include Advantage Family, Atopica, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its farm animal products include AviPro, Baytril, Catosal, Denagard, Experior, Hemicell, Maxiban/Monteban, Pulmotil, Rumensin, and Surmax. Its customers include consultants, veterinarians, farm animal producers and resellers.

Company Info

ELANCO ANIMAL HEALTH INC

450 Elanco Circle

Indianapolis INDIANA US

Employees: 9225

5EA Company Website

5EA Investor Relations

Phone: 18773526261

ELANCO ANIMAL HEALTH INC / 5EA.DE FAQ

Can you describe the business of ELANCO ANIMAL HEALTH INC?

Elanco Animal Health, Inc. develops, manufactures, and markets products for pets and farm animals. The company is headquartered in Indianapolis, Indiana and currently employs 9,000 full-time employees. The company went IPO on 2018-09-20. The firm's product portfolio is sold in more than 90 countries and serves animals across many species, primarily dogs and cats (collectively, pet health) and cattle, poultry, swine, and sheep (collectively, farm animal). The company has a diverse portfolio of products marketed under approximately 200 brands, including products for both pets and farm animals. The firm's global pet health portfolio is focused on parasiticides, vaccines and therapeutics. Its pet health products include Advantage Family, Atopica, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its farm animal products include AviPro, Baytril, Catosal, Denagard, Experior, Hemicell, Maxiban/Monteban, Pulmotil, Rumensin, and Surmax. Its customers include consultants, veterinarians, farm animal producers and resellers.


What is the current price of 5EA stock?

The current stock price of 5EA.DE is 21.715 EUR. The price increased by 4.22% in the last trading session.


Does ELANCO ANIMAL HEALTH INC pay dividends?

5EA.DE does not pay a dividend.


How is the ChartMill rating for ELANCO ANIMAL HEALTH INC?

5EA.DE has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What is the employee count for 5EA stock?

ELANCO ANIMAL HEALTH INC (5EA.DE) currently has 9225 employees.


Can you provide the ownership details for 5EA stock?

You can find the ownership structure of ELANCO ANIMAL HEALTH INC (5EA.DE) on the Ownership tab.